CASE REPORT: SPECIFIC ABL-INHIBITOR IMATINIB IS AN EFFECTIVE TARGETED AGENT AS THE FIRST LINE THERAPY TO TREAT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A CRYPTIC NUP214::ABL1 GENE FUSION

Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion

Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions, affecting a series of kinase genes, is associated with unfavorable prognosis, however, it could benefit from san jose sharks trucker hat treatment with tyrosine kinase inhibitors (TKI).NUP214::ABL1 fusion is detected in 6% of T-cell acute lymphoblastic leukemia (T-ALL), and is very

read more



A Retrospective Analysis of Reporting of Adverse Drug Reactions in a Tertiary Care Teaching Hospital: One Year Survey

Introduction: Pharmacovigilance (PV) is related to detection, assessment, understanding and prevention of Adverse Drug Reactions (ADRs) which are incurred when drug is made available in the market and used in different physiological conditions.In many countries, ADRs ranks among the top ten leading cause of morbidity and mortality.There is a lack o

read more